StockWatch
·
Pharmaceuticals
USFDA30 Oct 2026, 07:30 am

Rubicon Research Ambernath Facility Undergoes US FDA Inspection

AI Summary

Rubicon Research Ltd announced that its manufacturing facility in Ambernath, India, was inspected by the United States Food and Drug Administration (US FDA) from October 21 to October 29, 2026. The inspection was a comprehensive GMP inspection, in addition to a product application review. The US FDA issued a Form 483 with 3 observations related to system improvement and 2 observations related to the product application under review. All 5 observations are procedural and do not pertain to data integrity. The company is confident in its ability to address these observations and expects a timely conclusion to the evaluation. This inspection follows recent US FDA inspections of all the company's operational facilities.

Key Highlights

  • US FDA inspected Rubicon Research's Ambernath manufacturing facility.
  • Inspection yielded 5 procedural observations, not data integrity related.
  • Company confident in addressing observations and timely conclusion.
  • All operational facilities recently inspected by US FDA.